NuCana stock secures European patent protection for NUC-7738

Published on 10/01/2026 at 00:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NuCana stock gains a new intellectual-property milestone as Europe grants a composition-of-matter patent for NUC-7738. The candidate is in Phase 2 testing.

NCNA, GB00BD8P0H86, Illustration mit AI erstellt.

NuCana stock secured a new European intellectual-property milestone on September 30, 2026, when the European Patent Office granted patent EP 3683225 covering the chemical structure of NUC-7738. The candidate is being evaluated in the Phase 2 part of a Phase 1/2 study, giving the patent event direct relevance to the company's clinical pipeline.

Patent estate passes 85

According to StockTitan on September 30, 2026, NuCana said the new patent adds to protection comprising over 85 issued patents worldwide. Similar composition-of-matter patents had previously been granted in the United States and China, extending the geographic reach of the company's protection around NUC-7738.

The drug candidate is being studied as a monotherapy in advanced solid tumors and in combination with pembrolizumab for patients with PD-1 inhibitor-resistant metastatic melanoma. That clinical setting places the patent milestone alongside a development program that still depends on trial progress and future regulatory decisions.

Cash runway reaches 2029

Yahoo Finance reported on September 30, 2026, that NuCana expects its cash resources to fund planned operations into 2029. The company also said it aims to advance NUC-7738 and deliver milestones during the remainder of 2026, though those statements are forward-looking and depend on clinical and financing conditions.

NuCana describes itself as a clinical-stage biopharmaceutical company using its ProTide technology to develop cancer medicines. Its pipeline includes NUC-7738 and NUC-3373, while the investor-relations page identifies the company as focused on improving treatment outcomes in oncology.

Nasdaq context remains central

NCNA is listed on Nasdaq under the ticker NCNA. A September 30, 2026 market snapshot placed NuCana's market capitalization at USD 8.2 million and showed a 52-week range of USD 1.21 to USD 7.22. The small capitalization means the patent milestone is material to the investment narrative, but clinical execution remains the decisive checkpoint.